Matches in SemOpenAlex for { <https://semopenalex.org/work/W74443612> ?p ?o ?g. }
- W74443612 abstract "Abstract Progressive malignancy is a leading cause of death in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). To improve treatment of B-cell malignancies that persist despite alloHSCT, we conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. Ten patients were treated on this trial. Four patients were recipients of human-leukocyte-antigen (HLA)-matched unrelated donor (URD) transplants and 6 patients were recipients of HLA-matched sibling transplants. T cells for genetic modification were obtained from each patient’s healthy alloHSCT donor. Patients received a single infusion of anti-CD19-CAR T cells. Cell doses ranged from 1x106 to 10x106 T cells/kg. A mean of 58% of the infused cells expressed the CAR. Patients did not receive chemotherapy or other anti-malignancy therapy with the CAR-T-cell infusions, so the responses observed in these patients are not confounded by the effects of chemotherapy. In contrast to other reports of successful treatment of B-cell malignancies with anti-CD19-CAR T cells, the patients on this study were not lymphocyte-depleted at the time of the CAR-T-cell infusions. Two patients with chronic lymphocytic leukemia (CLL) refractory to standard unmanipulated allogeneic donor lymphocyte infusions (DLIs) had regressions of large malignant lymph node masses after infusion of allogeneic anti-CD19-CAR T cells. One of these CLL patients obtained a complete remission that is ongoing 9 months after treatment with allogeneic anti-CD19-CAR T cells. This patient also had complete eradication of blood B cells within 9 days after her CAR-T-cell infusion. Another patient had tumor lysis syndrome requiring rasburicase treatment as his CLL dramatically regressed in lymph nodes, bone marrow, and blood within 2 weeks of his anti-CD19-CAR-T-cell infusion. A patient with mantle cell lymphoma obtained a partial remission that is ongoing 3 months after infusion of anti-CD19-CAR T cells. A fourth patient with diffuse large B-cell lymphoma has ongoing stable disease 11 months after infusion of anti-CD19-CAR T cells. The other 6 treated patients all had short periods of stable malignancy or progressive disease after their CAR-T-cell infusions. Specific eradication of blood B cells occurred after infusion of CAR T cells in 3 of 4 patients with measurable blood B cells pretreatment. None of the patients treated on this study developed GVHD after their anti-CD19-CAR-T-cell infusions, despite the fact that 6 of 10 treated patients had experienced GVHD at earlier time-points after their most recent alloHSCT. One patient, who had a history of cardiac dysfunction with prior acute illnesses, had temporary cardiac dysfunction after infusion of anti-CD19-CAR T cells. The most prominent toxicities experienced by patients were fever and hypotension; these peaked 5 to 12 days after CAR-T-cell infusions and resolved within 14 days after the T-cell infusions. Two patients had Grade 3 fever, and 2 patients had Grade 3 hypotension. No patients experienced Grade 4 toxicities that were attributable to the CAR-T-cell infusions. Elevated levels of serum interferon gamma were detected in 3 patients at the time that they were experiencing toxicities. We detected cells containing the anti-CD19-CAR gene in the blood of 8 of 10 patients. The peak blood levels of CAR T cells varied from undetec to 2.8% of peripheral blood mononuclear cells. The persistence of the CAR T cells in the blood of patients was limited to one month or less. When we assessed T cells from the blood of patients ex vivo, we found elevated levels of the T-cell inhibitory molecule programmed cell death protein-1 (PD-1) on CAR+ T cells compared to CAR-negative T cells. These results show for the first time that small numbers of donor-derived allogeneic anti-CD19-CAR T cells can cause regression of highly treatment-resistant B-cell malignancies after alloHSCT without causing GVHD. Malignancies that were resistant to standard DLIs regressed after anti-CD19-CAR-T-cell infusions. Future goals for improving this approach include enhancing the persistence of anti-CD19-CAR T cells and reducing toxicities. Infusion of allogeneic T cells genetically modified to recognize malignancy-associated antigens is a promising approach for treating residual malignancy after alloHSCT. Disclosures: No relevant conflicts of interest to declare." @default.
- W74443612 created "2016-06-24" @default.
- W74443612 creator A5003258570 @default.
- W74443612 creator A5003738351 @default.
- W74443612 creator A5023659191 @default.
- W74443612 creator A5024858587 @default.
- W74443612 creator A5025810550 @default.
- W74443612 creator A5032315182 @default.
- W74443612 creator A5035585356 @default.
- W74443612 creator A5048942479 @default.
- W74443612 creator A5060647076 @default.
- W74443612 creator A5061239953 @default.
- W74443612 creator A5062706815 @default.
- W74443612 creator A5065897197 @default.
- W74443612 creator A5066218992 @default.
- W74443612 creator A5071013248 @default.
- W74443612 creator A5072133376 @default.
- W74443612 creator A5072313658 @default.
- W74443612 creator A5074220802 @default.
- W74443612 creator A5079704265 @default.
- W74443612 creator A5080222703 @default.
- W74443612 creator A5083072418 @default.
- W74443612 creator A5083522277 @default.
- W74443612 creator A5086602479 @default.
- W74443612 creator A5089893290 @default.
- W74443612 creator A5090875956 @default.
- W74443612 date "2013-11-15" @default.
- W74443612 modified "2023-10-15" @default.
- W74443612 title "Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation" @default.
- W74443612 doi "https://doi.org/10.1182/blood.v122.21.151.151" @default.
- W74443612 hasPublicationYear "2013" @default.
- W74443612 type Work @default.
- W74443612 sameAs 74443612 @default.
- W74443612 citedByCount "7" @default.
- W74443612 countsByYear W744436122017 @default.
- W74443612 countsByYear W744436122018 @default.
- W74443612 countsByYear W744436122019 @default.
- W74443612 countsByYear W744436122021 @default.
- W74443612 countsByYear W744436122022 @default.
- W74443612 crossrefType "journal-article" @default.
- W74443612 hasAuthorship W74443612A5003258570 @default.
- W74443612 hasAuthorship W74443612A5003738351 @default.
- W74443612 hasAuthorship W74443612A5023659191 @default.
- W74443612 hasAuthorship W74443612A5024858587 @default.
- W74443612 hasAuthorship W74443612A5025810550 @default.
- W74443612 hasAuthorship W74443612A5032315182 @default.
- W74443612 hasAuthorship W74443612A5035585356 @default.
- W74443612 hasAuthorship W74443612A5048942479 @default.
- W74443612 hasAuthorship W74443612A5060647076 @default.
- W74443612 hasAuthorship W74443612A5061239953 @default.
- W74443612 hasAuthorship W74443612A5062706815 @default.
- W74443612 hasAuthorship W74443612A5065897197 @default.
- W74443612 hasAuthorship W74443612A5066218992 @default.
- W74443612 hasAuthorship W74443612A5071013248 @default.
- W74443612 hasAuthorship W74443612A5072133376 @default.
- W74443612 hasAuthorship W74443612A5072313658 @default.
- W74443612 hasAuthorship W74443612A5074220802 @default.
- W74443612 hasAuthorship W74443612A5079704265 @default.
- W74443612 hasAuthorship W74443612A5080222703 @default.
- W74443612 hasAuthorship W74443612A5083072418 @default.
- W74443612 hasAuthorship W74443612A5083522277 @default.
- W74443612 hasAuthorship W74443612A5086602479 @default.
- W74443612 hasAuthorship W74443612A5089893290 @default.
- W74443612 hasAuthorship W74443612A5090875956 @default.
- W74443612 hasConcept C126322002 @default.
- W74443612 hasConcept C203014093 @default.
- W74443612 hasConcept C2776090121 @default.
- W74443612 hasConcept C2777408962 @default.
- W74443612 hasConcept C28328180 @default.
- W74443612 hasConcept C2911091166 @default.
- W74443612 hasConcept C3875195 @default.
- W74443612 hasConcept C54355233 @default.
- W74443612 hasConcept C71924100 @default.
- W74443612 hasConcept C86803240 @default.
- W74443612 hasConcept C8891405 @default.
- W74443612 hasConceptScore W74443612C126322002 @default.
- W74443612 hasConceptScore W74443612C203014093 @default.
- W74443612 hasConceptScore W74443612C2776090121 @default.
- W74443612 hasConceptScore W74443612C2777408962 @default.
- W74443612 hasConceptScore W74443612C28328180 @default.
- W74443612 hasConceptScore W74443612C2911091166 @default.
- W74443612 hasConceptScore W74443612C3875195 @default.
- W74443612 hasConceptScore W74443612C54355233 @default.
- W74443612 hasConceptScore W74443612C71924100 @default.
- W74443612 hasConceptScore W74443612C86803240 @default.
- W74443612 hasConceptScore W74443612C8891405 @default.
- W74443612 hasLocation W744436121 @default.
- W74443612 hasOpenAccess W74443612 @default.
- W74443612 hasPrimaryLocation W744436121 @default.
- W74443612 hasRelatedWork W1966542058 @default.
- W74443612 hasRelatedWork W2087055812 @default.
- W74443612 hasRelatedWork W2105400883 @default.
- W74443612 hasRelatedWork W2118796952 @default.
- W74443612 hasRelatedWork W2130338247 @default.
- W74443612 hasRelatedWork W2145985838 @default.
- W74443612 hasRelatedWork W2167550136 @default.
- W74443612 hasRelatedWork W2170513194 @default.
- W74443612 hasRelatedWork W2461019365 @default.
- W74443612 hasRelatedWork W2530236591 @default.
- W74443612 hasRelatedWork W2557037793 @default.